Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

A trade group representing large compounding pharmacies sued the FDA over its removal of a widely prescribed Lilly diabetes ...

On the efficacy issue, Merck told ... develop severe COVID-19 than men. On the other hand, there were also more older people later on, which should have benefited the active drug.

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Merck's Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) in Phase 3 trial for newly diagnosed head ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE ...

Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III ... The Historic Significance of Improving on a Best-Selling Drug: Regeneron One of the largest ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.